Kalaris Therapeutics is covered by a small group of Wall Street firms, and their targets are unusually dispersed. Verified individual price targets include Piper Sandler at $7 (Hold, March 2026), Morgan Stanley at $14 (Overweight, initiated April 2026 and reiterated August 2026), Wedbush at $17 (Outperform, initiated May 2026 and maintained), Chardan Capital at $19 (Buy, December 2025), and Citizens JMP at $25 (Outperform, May 2026). Averaging these five targets produces a mean of $16.40, which rounds to the $16 central target used here. Independent aggregators report slightly different consensus figures — roughly $15.50 to $18.75 — reflecting different analyst sets and timestamps rather than disagreement over direction.
An important caveat applies: most of these targets were set between December 2025 and August 2026, before the stock's sharp decline. As a result, the analyst price target range reflects a pre-decline view and may not yet have "caught up" to the current price. The bull case centers on TH103's differentiation and durability; the cautious case, represented by the lone Hold rating, reflects financing and clinical-execution risk.
Shares of Kalaris Therapeutics trade near $2.00, within a 52-week range of roughly $1.78 to $11.88 and down about 58% to 60% over the past year. Reaching the $16 central target would require a gain of about 700% — a very large move. The company is pre-revenue, with roughly $93 million in cash, minimal debt, and a market capitalization near $46 million to $48 million. Because the stock is driven almost entirely by clinical catalysts rather than fundamentals such as earnings or revenue, its path toward any higher level depends on positive data readouts and renewed financing confidence rather than incremental operating progress.
The central investment thesis is TH103, Kalaris's candidate for wet AMD. Expanded Phase 1a results showed encouraging efficacy signals, including functional and structural improvements and the potential for longer treatment durability, which analysts view as a possible differentiator in the roughly $15 billion anti-VEGF market. Upcoming Phase 1b/2 multiple-dose data, expected in the first half of 2027, is the key catalyst. A clean balance sheet with substantial cash and low leverage also supports the company's ability to fund development, and recent strengthening of its financial leadership has been cited as a positive for future capital access.
The obstacles are substantial. Kalaris generates no revenue, and its negative cash generation means it must continue raising capital while programs remain in development. The share count has increased more than 40% year over year, and a December 2025 private placement plus an at-the-market offering of up to $100 million create ongoing dilution risk. Shrinking shareholders' equity reflects cumulative losses, and the wet-AMD space is crowded with established therapies, meaning TH103 must demonstrate clear differentiation to justify commercial value. Any clinical setback, safety concern, or financing difficulty could weigh heavily on a pre-revenue biotech with a small float.
The stock trades well below both its 50-day moving average (near $2.63) and 200-day moving average (near $5.10), indicating a persistent downtrend. The 52-week low near $1.78 is the nearest support level to watch, while the former range in the $4 to $5 area represents overhead resistance. A sustained move toward the analyst-derived target would first require reclaiming these moving averages and the psychologically important $5 level, a substantial technical recovery from current prices.
Analyst price targets typically reflect a research horizon of about 12 months, though the actual horizon varies by firm and most of these targets predate the recent decline. The single most important upcoming item is the Phase 1b/2 multiple-dose data for TH103 expected in the first half of 2027. Investors should also monitor quarterly cash balances and burn rates, any new financing or dilution announcements, analyst target revisions following the data, and sector-wide sentiment toward clinical-stage biotech and anti-VEGF therapies. No specific timing for reaching any target can be assumed.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name like Kalaris Therapeutics, these signals can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual chart review. Explore the signals to complement your own research and stay alert to shifting momentum.
The $16 central target for Kalaris Therapeutics is the arithmetic mean of five verified analyst targets spanning roughly $7 to $25, and it sits about 700% above the current price — a very large, low-probability near-term move that depends almost entirely on clinical success. The bull case rests on TH103's early efficacy and durability signals in a large wet-AMD market, supported by a healthy cash position. The bear case rests on zero revenue, persistent cash burn, heavy dilution, and a stock mired in a downtrend below all major moving averages. With Phase 1b/2 data not expected until the first half of 2027, the gap between the current price and the analyst-derived target is best understood as a reflection of pre-decline optimism rather than a near-term forecast. Investors should watch the data readout, cash runway, and financing decisions as the decisive variables.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with PTHS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then PTHS could also see price increases.
| Ticker / NAME | Correlation To KLRS | 1D Price Change % | ||
|---|---|---|---|---|
| KLRS | 100% | -18.70% | ||
| PTHS - KLRS | 43% Loosely correlated | -5.02% | ||
| CGEN - KLRS | 29% Poorly correlated | -2.34% | ||
| CAMP - KLRS | 28% Poorly correlated | -7.68% | ||
| MESO - KLRS | 27% Poorly correlated | -3.12% | ||
| RCKT - KLRS | 26% Poorly correlated | -3.16% | ||
More | ||||